ClinicalTrials.Veeva

Menu
S

Shepherd Center, Inc. | Hulse Spinal Cord Injury Lab

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Fampridine
Ocrelizumab
Interferon
Ziconotide
AV650
Natalizumab
Elezanumab
Ofatumumab
glatiramer acetate
Rebif

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 65 total trials

A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis

This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerabilit...

Enrolling
Multiple Sclerosis
Biological: IMS001

Primary Objective: To further evaluate the aspects of safety related to PoNS therapy in chronic stroke survivors.Secondary Objectives: To further eva...

Enrolling
Chronic Stroke Survivors
Device: Portable Neuromodulation Stimulator (PoNS)

Open-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identi...

Active, not recruiting
Multiple Sclerosis, Relapsing
Drug: Ocrelizumab

Acute Spinal Cord Injury (SCI) is a rare injury that leads to permanent neuromotor impairment and sudden disability. Approximately 25,000 people expe...

Active, not recruiting
Spinal Cord Injury (SCI)
Drug: Placebo
Drug: Elezanumab

This study is designed is to test the feasibility, fidelity, and effectiveness of scaling up an evidence- and theory-based virtually delivered physic...

Active, not recruiting
Spinal Cord Injuries
Behavioral: WOWii Program

This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of...

Active, not recruiting
Relapse Remitting Multiple Sclerosis
Drug: Ofatumumab

This multicenter, randomized, double-blind, sham-controlled study is designed to evaluate the efficacy and safety of the iovera° system in subjects w...

Enrolling
Spasticity, Cerebral or Spinal Condition
Device: iovera° system
Device: sham iovera° system treatment

The purpose of this study is to compare the efficacy and safety of intravenous (IV) infusions of MT-3921 to placebo in subjects with acute traumatic...

Active, not recruiting
Spinal Cord Injury
Biological: Placebo
Biological: MT-3921

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressiv...

Active, not recruiting
Multiple Sclerosis
Drug: Placebo matching IMU-838
Drug: IMU-838

This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized...

Enrolling
Relapsing Remitting Multiple Sclerosis
Drug: Placebo
Drug: PIPE-307 Dose A

Trial sponsors

S
Acorda Therapeutics logo
L
Boston Scientific logo
H
Jazz Pharmaceuticals logo
O
P
Roche logo
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems